WARREN GOLDENBERG: Open Payments
NPI 1497053706 · SANTA FE, NM. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$768 in 36 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $94 · 2025 $768
Food & beverage: $768
| Company | Payments | Amount |
|---|---|---|
| Viatris Specialty LLC | 6 | $166 |
| AstraZeneca Pharmaceuticals LP | 4 | $82 |
| Novo Nordisk Inc | 3 | $70 |
| Astellas Pharma US Inc | 3 | $66 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $47 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $37 |
| Merck Sharp & Dohme LLC | 2 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Novartis Pharmaceuticals Corporation | 1 | $31 |
| PFIZER INC. | 2 | $28 |
Products named: YUPELRI, Ozempic, Veozah, XIFAXAN, JOURNAVX, CAPVAXIVE, PLUVICTO, PAXLOVID.
Industry payments across NM — which companies pay providers there.
